Peptide Therapy for Inflammation: A New Solution BPC 157 Dosing (Common Protocols), Oral Subcutaneous, 500 mcg daily, Duration: 6 weeks, Intramuscular Peritendinous, 1 mg daily, Duration: 6 weeks, Note:, Not approved by FDA or BPC 157 Benefits, Dosage & Before After Results Is BPC 157 Banned? Oral vs. Injectable Forms Explained The Human Lab Rats Injecting Themselves with Peptides Office for Science and Society McGill University Oral Peptides: FAQs on Bioavailability, Safety, and Clinical Use AJMC